These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 779492)

  • 1. Enhancement of tissue invasion in murine aspergillosis by systemic administration of suspensions of killed Corynebacterium parvum.
    Purnell DM
    Am J Pathol; 1976 Jun; 83(3):547-56. PubMed ID: 779492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Corynebacterium parvum on the course of a Listeria monocytogenes infection in normal and congenitally athymic (nude) mice.
    Ruittenberg EJ; van Noorle Jansen LM
    Zentralbl Bakteriol Orig A; 1975; 231(1-3):197-205. PubMed ID: 808049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of thermal response of normal and malignant tissues by Corynebacterium parvum.
    Urano M; Yamashita T; Suit HD; Gerweck LE
    Cancer Res; 1984 Jun; 44(6):2341-7. PubMed ID: 6722772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vaccine prepared from Corynebacterium parvum on the growth of Gardner lymphosarcoma in C3H strain mice.
    Motycka K; Chudomel V; Bednár M; Bostík J
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):405-12. PubMed ID: 6549499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced resistance of mice to Mycoplasma pulmonis-induced arthritis by administration of killed Corynebacterium parvum.
    Keystone EC; Taylor-Robinson D; Ling L; Pope C; Metcalfe A; Furr P; Fornasier V
    Clin Exp Immunol; 1981 Nov; 46(2):355-62. PubMed ID: 7337973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virulence of catalase-deficient aspergillus nidulans in p47(phox)-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease.
    Chang YC; Segal BH; Holland SM; Miller GF; Kwon-Chung KJ
    J Clin Invest; 1998 May; 101(9):1843-50. PubMed ID: 9576747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.
    Scott MT; Milas L
    Cancer Res; 1977 Jun; 37(6):1673-9. PubMed ID: 870181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice.
    Berd DA; Mitchell MS
    Cancer Res; 1976 Nov; 36(11 Pt 1):4119-24. PubMed ID: 975053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of resistance to ectromelia virus infection by corynebacterium parvum in murine peritoneal macrophages.
    Cohen DA; Bubel HC
    J Reticuloendothel Soc; 1983 Jan; 33(1):35-46. PubMed ID: 6300395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection by polyI:polyC against infection with herpes simplex virus in mice pretreated with Corynebacterium parvum.
    Storch E; Baumgartl D; Kirchner H
    Nat Immun Cell Growth Regul; 1983-1984; 3(3):134-42. PubMed ID: 6209572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunomodulation on the fate of tumor cells in the central nervous system and systemic organs of mice. Distribution of [125I]5-Iodo-2'-deoxyuridine-labeled KHT tumor cells after left intracardial injection.
    Conley FK
    J Natl Cancer Inst; 1982 Aug; 69(2):465-73. PubMed ID: 6955547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
    Lichtenstein AK; Berek J; Kahle J; Zighelboim J
    Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of C3H mice bearing solid Gardner lymphosarcoma with vaccine prepared from Corynebacterium parvum combined with methotrexate and Alexan.
    Motycka K; Chudomel V; Bednár M; Bostík J
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):413-9. PubMed ID: 6549500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of interleukin-10 at the time of priming protects Corynebacterium parvum-primed mice against LPS- and TNF-alpha-induced lethality.
    Smith SR; Terminelli C; Denhardt G; Narula S; Thorbecke GJ
    Cell Immunol; 1996 Nov; 173(2):207-14. PubMed ID: 8912878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative tissue invasion of the murine brain as a phenotypic marker of strain virulence in Aspergillus nidulans.
    Purnell DM
    Sabouraudia; 1975 Jul; 13(2):209-16. PubMed ID: 1099700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.
    Krahenbuhl JL; Lambert LH; Remington JS
    Immunology; 1976 Dec; 31(6):837-46. PubMed ID: 992714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Corynebacterium parvum on the response to irradiation of a C3H fibrosarcoma.
    Suit HD; Sedlacek R; Wagner M; Orsi L; Silobrcic V; Rothman KJ
    Cancer Res; 1976 Apr; 36(4):1305-14. PubMed ID: 1260756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
    Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
    Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.